Celgene Archives | PharmaShots

Celgene Collaborates with Presage to Evaluate Therapies with its CIVO Technology for Multiple Cancers

May 3, 2019May 7, 2019Tuba Khan

Shots: Presage utilizes its CIVO intratumoral microdosing platform to evaluate Celgene’s early stage products in P-0 trial The collaboration follows safety & feasibility [...]

Celgene and Acceleron Pharma Submit Biologics License Application (BLA) to the US FDA for Luspatercept

April 8, 2019April 24, 2019Tuba Khan

Shots: The BLA submission is based on P-III MEDALIST & BELIEVE studies. The P-III MEDALIST study involves assessing of luspatercept (1.0 mg/kg) vs [...]

Celgene Files NDA for Ozanimod to the US FDA for Relapsing Forms of Multiple Sclerosis (RMS)

March 26, 2019April 24, 2019Tuba Khan

Shots: The NDA filing is based on P-III SUNBEAM & RADIANCE studies assessing Ozanimod vs Avonex in 1,346 & 1,320 patients with RMS [...]

Celgene Collaborates with Exscientia for its AI Drug Discovery Platform

March 22, 2019April 24, 2019Shiwani Sharma

Shots: Celgene & Exscientia enter into a 3yrs. partnership to accelerate the development of small molecules for three therapeutic programs for Celgene using [...]

Celgene’s Fedratinib Receives FDA’s Priority Review to NDA Filing for Myelofibrosis

March 6, 2019April 24, 2019Shiwani Sharma

Shots: Celgene announces the acceptance of Fedratinib’s NDA based on P-III JAKARTA study assessing Fedratinib (400mg/500mg) vs PBO in 289 patients with primary [...]

Philogen Collaborates with Johnson&Johnson (J&J), Novartis and Celgene

January 24, 2019April 25, 2019Shiwani Sharma

Shots: Philogen collaborates with J&J to discover & develop therapies utilizing Philochem’s technology (a Swizz subsidiary of Philogen) for serious conditions Philogen signs [...]

Celgene Signs an Exclusive WW License Option with Obsidian for DDs Technology

January 21, 2019April 25, 2019Shiwani Sharma

Shots: Celgene to utilize Obsidian’s DDs (Destabilizing Domains) technology for its cell therapy candidates with DD-regulated IL12 or CD40L proteins for oncology indications [...]

Bristol-Myers Squibb (BMS) to Acquire Celgene for $74B

January 3, 2019April 25, 2019Shiwani Sharma

Shots: BMS acquires Celgene, in all stock transaction for $74B. Celgene to receive $50/share, 1 BMS share and 1 Contingent Value Right (CVR) [...]

Celgene Licenses Aprinoia’s APN-1607 an Imaging Tracer, for Neurodegenerative Diseases

January 3, 2019April 25, 2019Shiwani Sharma

Shots: Celgene to get non-exclusive rights for Aprinoia’s bAPN-1607 and Aprinoia to receive license and usage fee annually The focus of the agreement [...]